Clinical Trial Results: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial results of NT-I7 after CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma show early efficacy signals and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma

Drugs mentioned

• CD19 CAR-T cell therapy (CAR-T cell therapy targeting CD19)
• NT-I7

Snippet

Sponsor: NeoImmuneTech | Conditions: Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2026-08-10